Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bristol Myers Squibb Co | 40 |
| 2 | Massachusetts Institute of Technology | 35 |
| 3 | Otsuka Holdings Co Ltd | 33 |
| 4 | Mass General Brigham Inc | 25 |
| 5 | Institut National de la Santé et de la Recherche Médicale | 20 |
| 6 | German Cancer Research Center | 19 |
| 7 | The University of Texas System | 15 |
| 8 | University of Southern California | 14 |
| 9 | Harvard University | 13 |
| 10 | Centre National de la Recherche Scientifique | 12 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 522 |
| 2 | A61K | Medicinal preparations | 513 |
| 3 | C12N | Microorganisms, enzymes | 205 |
| 4 | C12Q | Measuring/testing involving enzymes | 190 |
| 5 | C07K | Peptides | 164 |
| 6 | G01N | Investigating / analysing materials | 122 |
| 7 | C07D | Heterocyclic compounds | 82 |
| 8 | C07H | Sugars and derivatives | 82 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 38 |
| 10 | Y02A | Climate change adaptation | 34 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| SPATIAL ANALYSIS OF DNA METHYLATION | 2021 | 10X Genomics Inc | 101 |
| WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS | 2009 | Massachusetts Institute of Technology | 146 |
| MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | 2017 | Gilead Sciences Inc | 53 |
| IMPROVED CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 | 2011 | Immatics NV | 85 |
| COMPOSITIONS AND METHODS FOR ENHANCING CELL REPROGRAMMING | 2010 | Massachusetts Institute of Technology | 88 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | James G. Herman | Johns Hopkins University | 4 |
| 2 | John D. Minna | The University of Texas Southwestern Medical Center | 3 |
| 3 | Jorge Oliveira | Instituto Português de Oncologia Francisco Gentil | 2 |
| 4 | Rolf I. Skotheim | University of Oslo | 2 |
| 5 | Vundavalli V. Murty | Cancer Genetics (United States) | 2 |
| 6 | Eline Menu | Vrije Universiteit Brussel | 2 |
| 7 | Els Van Valckenborgh | Vrije Universiteit Brussel | 2 |
| 8 | Qing Chang | Prince of Wales Hospital | 2 |
| 9 | Jane A. Plumb | Cancer Research UK | 2 |
| 10 | Joäo Carvalho | Instituto Português de Oncologia Francisco Gentil | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine | 2008 | 953 | HIV Research and Treatment |
| Strategies for reversing drug resistance | 2003 | 357 | Epigenetics and DNA Methylation |
| Mechanisms of metastasis | 2008 | 296 | Cancer Cells and Metastasis |
| Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene | 2001 | 279 | Cancer-related molecular mechanisms research |
| Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes | 2006 | 256 | Epigenetics and DNA Methylation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 5-Aza-1-(2-deoxy-beta-D-ribofuranosyl)cytosine?
Which organizations hold the most patents for this compound?
What is the overall patent and publication activity for this compound?
What are the primary technology classifications associated with patents for this compound?
What research topics have been covered in the published literature on this compound?